These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22209775)

  • 1. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
    Carrara L; Guzzo F; Roque DM; Bellone S; Emiliano C; Sartori E; Pecorelli S; Schwartz PE; Rutherford TJ; Santin AD
    Gynecol Oncol; 2012 Apr; 125(1):231-6. PubMed ID: 22209775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
    Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD
    Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
    Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of patupilone resistance.
    Mozzetti S; Iantomasi R; De Maria I; Prislei S; Mariani M; Camperchioli A; Bartollino S; Gallo D; Scambia G; Ferlini C
    Cancer Res; 2008 Dec; 68(24):10197-204. PubMed ID: 19074887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.
    Roque DM; Buza N; Glasgow M; Bellone S; Bortolomai I; Gasparrini S; Cocco E; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Clin Exp Metastasis; 2014 Jan; 31(1):101-10. PubMed ID: 24005572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
    Mok TS; Choi E; Yau D; Johri A; Yeo W; Chan AT; Wong C
    Oncology; 2006; 71(3-4):292-6. PubMed ID: 17657173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
    Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
    Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-200c and HuR in ovarian cancer.
    Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.
    Mozzetti S; Martinelli E; Raspaglio G; Prislei S; De Donato M; Filippetti F; Shahabi S; Scambia G; Ferlini C
    Biochem Pharmacol; 2012 Dec; 84(11):1409-18. PubMed ID: 22964220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.